Kumode, Takahiro
2 papers on CoChatORCID 0000-0002-4799-5362
Most cited papers
- Verified
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., et al. (2026) · The Lancet
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 41
- Verified
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial
Sehn, L. H., Hübel, K., Luminari, S., Scholz, C. W., Salar, A., Paneesha, S., Wahlin, B. E., Panayiotidis, P., Lee, H.-P., Jiménez-Ubieto, A., et al. (2026) · The Lancet
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 25
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free